Cambridge, UK-based biopharmaceutical company Wren Therapeutics has completed the closing of £12.4m financing, taking its total capital raised to date to around £33m.
The latest financing round was led by the company’s existing shareholder The Baupost Group, with new investors including Schooner Capital and Industry Ventures. Other existing investors, including LifeForce Capital, also participated.
Wren, a spin-off company from both the University of Cambridge in the UK and Lund University in Sweden, is focused on drug discovery and development for the treatment of protein misfolding diseases.
The company has utilised the capital raised so far to advance its lead small molecule programmes, targeting amyloid-beta and alpha-synuclein – with the first clinical candidate for amyloid-β set for Q1 2021.
Last December, Wren also signed a research collaboration agreement with Eisai to discover new small molecules for the potential treatment of synucleinopathies.
Synucleinopathies are neurodegenerative disease characterised by the misfolding and aggregation of a-synuclein in neurons and glial cells.
This includes Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy.
Wren has also expanded its pipeline to included three additional targets – including IAAP for diabetes, tua for Alzheimer’s disease and other tauopathies, and TDP-43 for motor neurone disease.
“The new capital, alongside our recently announced collaboration with Eisai, is a further endorsement of our unique chemical kinetics platform that has been industrialised by the Wren team over the previous four years, building on more than a decade of prior academic research,” said Samuel Cohen, chief executive officer of Wren.
“Our mission is to radically advance drug discovery for a wide range of protein misfolding diseases by creating molecules that will offer transformative therapeutic options for millions of patients globally suffering from these increasingly common medical disorders,” he added.
by Lucy Parsons
Source: pharmatimes.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
